Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BLOCK/CKD
2019-001579-35Phase 2Completed
- Sponsor
- KBP Biosciences
- Start
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hypertension (HTN) and chronic kidney disease (CKD) comparing KBP-5074 with Placebo (2 arms). Primary endpoint: Change in trough cuff resting seated systolic blood pressure. Started Jun 2019; status: completed.
02
Drugs
ocederenone
03
Conditions
hypertension (HTN)chronic kidney disease (CKD)
Beyond the preview
Go deeper on 2019-001579-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001579-35.